Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Approvals/SFDA/YUPELRI 175 mcg / 3 ml

Authorized

NCE

YUPELRI 175 mcg / 3 ml

Unknown🇸🇦 Saudi Food and Drug Authority

Approval Date: N/A
Approval ID: fa150b3f87573802
Company: Unknown
Type: NCE

Approval Details

Approval Id: fa150b3f87573802
Drug Approval Sfda Name: YUPELRI 175 mcg / 3 ml
Trade Name: YUPELRI 175 mcg / 3 ml
Generic Name: REVEFENACIN
Register Number: 0908222443
Register Year: 2022
Drug Type: NCE
Route Of Administration: Inhalation use
Package Type: Single Dose Container
Package Size: 30
Size: 3
Size Unit: ml
Legal Status: Prescription
Authorization Status: Valid
Marketing Status: Marketed
Product Control: Uncontrolled
Storage Conditions: store below 30°c
Shelf Life: 36 Months
Distribution Site: Pharmacy
Description Code: 7000002311-175-100000074070
Price: 306.5

Active Ingredients

Authorized

Quick Info

Agency

SFDA

Country

🇸🇦

Approval ID

fa150b3f87573802

Type

NCE

Back to SFDA Approvals

YUPELRI 175 mcg / 3 ml - SFDA Drug Approval Details